Corbus Posts $37.8M Q3 Loss; $115.3M Cash Funds Operations Into 2028
CRBP sits 25% above its 52-week low of $2.81.
Summary
Corbus reported a $37.8M Q3 2026 net loss, or $37.75 million, inflated by a $15.0M licensing milestone, and said $115.3M in cash and investments funds operations into 2028. The $1.81 per-share loss missed the $1.21 mean analyst estimate, with revenue of zero against $1.25M expected. CANYON-1 obesity data will be presented at ObesityWeek on November 15, 2026.
Updated with a Reuters report · What changed
Updates
· Reuters — Corbus's Q3 loss of $1.81 per share missed the $1.21 mean analyst estimate; revenue was zero versus $1.25M expected.
- Wall Street expected results to range from $-1.91 to -73 cents per share.
- Quarterly loss of $37.75 million.
Key Events · Earnings and Guidance · CRBP
-
Updated · · Reuters
Q3 Loss Widens to $37.8M, Missing Estimates
Net loss of $37.8M, or $1.81 per basic and diluted share, versus $23.3M, or $1.90 per share, in Q3 2025; the quarterly loss of $37.75 million, or $1.81 per share, missed the $1.21 mean analyst estimate, with Wall Street expecting results from $-1.91 to -73 cents per share, and revenue was zero versus $1.25M expected.
-
Milestone Drives Expense Increase
Operating expenses rose $14.4M to $38.8M, primarily from a $15.0M development milestone under the CSPC license for sutantatug envedotin.
-
Cash Runway Into 2028
$115.3M of cash, cash equivalents and investments at September 30, 2026 is expected to fund operations into 2028 under current plans.
-
Share Count Up on ATM Use
Weighted average shares outstanding were 20,837,787 versus 12,307,298 a year earlier; 20,606,760 shares were outstanding at September 30, 2026 against 300,000,000 authorized.
Analysis · CRBP · Life Sciences
The headline loss widened to $37.8M from $23.3M a year ago, but $15.0M of that increase is a one-time CSPC licensing milestone rather than a step-up in ongoing spend. Against the Street the quarter fell short: the quarterly loss of $37.75 million, or $1.81 per share, missed the $1.21 mean analyst estimate, within a range of expectations from $-1.91 to -73 cents per share, and revenue of zero came in against $1.25M expected. More important for a clinical-stage biotech, $115.3M of cash and investments is expected to fund operations into 2028, covering the TEMPO-1 registrational readout path and the CRB-913 development plan without an immediate financing. The share count has already grown to 20.8M weighted average from 12.3M a year earlier, reflecting the ATM usage previously disclosed, so per-share losses are being spread over a larger base. Next concrete data point is the late-breaking CANYON-1 obesity poster at ObesityWeek on November 15, 2026.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $3.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.1M. The 52-week trading range was $2.81 to $12.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.